PBC | PharmaTimes

Silent plight

John Pinching — Fri, 03 May 2024 11:43:55 +0000

Why a new approach is needed for primary biliary cholangitis trials

End of the line for Genfit’s experimental NASH drug

Selina McKee — Thu, 23 Jul 2020 09:05:00 +0000

Development of elafibranor will be discontinued for NASH, with the company now focusing on its future as a treatment for PBC

FDA warning on Intercept’s Ocaliva after patient deaths

Selina McKee — Fri, 22 Sep 2017 11:05:00 +0000

US regulators have issued a safety communication warning of the risk for serious liver injury and death from incorrect dosing of Intercept Pharmaceuticals' Ocaliva in patients with primary biliary cholangitis.

Ocalvia gets NHS green light for rare chronic liver disease

Selina McKee — Thu, 27 Apr 2017 11:28:00 +0000

Intercept's Ocaliva has been issued a final green light for use by the NHS to treat the rare chronic liver disease primary biliary cholangitis (PBC), which affects around one in 1,000 women over the age of 40 but is still the leading cause of liver transplantation in adult women in the UK.

NICE backs new treatment for chronic liver disease

Selina McKee — Fri, 03 Mar 2017 13:50:00 +0000

Intercept's Ocaliva is being backed by the National Institute for Health and Care Excellence for routine NHS commissioning as a treatment for people with the chronic liver disease primary biliary cholangitis (PBC).

EU approves new therapy for rare liver condition PBC

Selina McKee — Thu, 15 Dec 2016 10:18:00 +0000

The European Commission has cleared Intercept's Ocaliva for the treatment of primary biliary cholangitis (PBC), giving patients the potential to access the first new therapy for the condition in nearly 20 years.